SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-23-278039
Filing Date
2023-11-16
Accepted
2023-11-15 18:22:25
Documents
2
Group Members
ABV SPV I GP LLC ABV SPV GPAVALON BIOVENTURES GP LLC ABV GPAVALON BIOVENTURES I LP ABV IAVALON BIOVENTURES SPV I L.P. ABV SPVAVALON VENTURES XI GP LLC AVALON XI GPBRADEN BOHRMANN BOHRMANNJAY LICHTER PH.D. LICHTERKEVIN KINSELLARICHARD LEVANDOV LEVANDOVSANF

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d943966dsc13da.htm SC 13D/A 282180
2 EX-99.C d943966dex99c.htm EX-99.C 12103
  Complete submission text file 0001193125-23-278039.txt   296297
Mailing Address 1134 KLINE STREET LA JOLLA CA 92037
Business Address 1134 KLINE STREET LA JOLLA CA 92037 8583482180
Avalon Ventures XI, L.P. (Filed by) CIK: 0001652901 (see all company filings)

IRS No.: 474748883 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Subject) CIK: 0001817713 (see all company filings)

IRS No.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-92596 | Film No.: 231411883
SIC: 2834 Pharmaceutical Preparations